AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

The waiting time paradox: population based retrospective study of treatment delay and survival of women with endometrial cancer in Scotland. (Papers).

British Medical Journal

| July 27, 2002 | Crawford, Simon C; Davis, Jonathan A; Siddiqui, Nadeem A; de Caestecker, Linda; Gillis, Charles R; Hole, David | COPYRIGHT 2003 British Medical Association. (Hide copyright information)Copyright

Delay in the delivery of treatment for gynaecological cancers has been previously investigated. (1 2) In some cases, the delay reflects the illness behaviour of women; in others, it was inherent in the system for delivering health care. Few studies have linked delay in treatment with survival, although a study from Israel found that survival from endometrial cancer was not affected by a delay in treatment of four months). (3)

We investigated links between delays in treatment and survival, using a recently completed audit of endometrial cancer treatment in Scotland.

Methods and results

We collected data from the case notes of all women resident in Scotland who were diagnosed between 1 January 1996 and 31 December 1997 as having endometrial carcinoma. Of 781 cases, we found case notes for 714, and, out of these, we analysed the 703 cases that involved operative treatment.

We calculated time intervals from the dates of general practitioner referral letters, clinic appointments, …

Related articles from newspapers, magazines, journals, and more
Chemotherapy After Surgery Reduces Recurrence, Extends Survival for Patients...
News wire article from: Europe Intelligence Wire December 5, 2005 700+ words
Aeterna Zentaris unveils final Phase II data for AEZS108 in advanced...
News wire article from: Europe Intelligence Wire September 15, 2011 700+ words
AEterna Zentaris presents positive Phase II efficacy and safety data for...
News wire article from: Chemical Business Newsbase November 18, 2010 700+ words
Aeterna Zentaris presents positive Phase II efficacy and safety data for...
News wire article from: Chemical Business Newsbase November 18, 2010 700+ words
Aeterna Zentaris reports Phase II data for AEZS108 in advanced endometrial...
News wire article from: Europe Intelligence Wire November 19, 2010 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily